tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

enVVeno Medical Faces Nasdaq Delisting Notice

Story Highlights
enVVeno Medical Faces Nasdaq Delisting Notice

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

enVVeno Medical ( (NVNO) ) has shared an update.

On October 7, 2025, enVVeno Medical Corporation was notified by Nasdaq that its common stock had fallen below the $1.00 per share minimum bid price requirement for 30 consecutive business days, putting it out of compliance with Nasdaq’s listing rules. The company has until April 6, 2026, to regain compliance by ensuring its stock closes at or above $1.00 for at least 10 consecutive trading days. Failure to comply could lead to delisting, though the company may qualify for an additional compliance period and has the right to appeal any delisting decision.

Spark’s Take on NVNO Stock

According to Spark, TipRanks’ AI Analyst, NVNO is a Neutral.

enVVeno Medical’s overall stock score is influenced by its robust technical performance, which is somewhat overshadowed by challenging financial metrics. The company faces significant profitability issues, as reflected by its negative income and cash flow figures, despite having a stable balance sheet. While technical indicators show strong upward momentum, valuation concerns due to a negative P/E ratio and lack of dividends weigh on the score.

To see Spark’s full report on NVNO stock, click here.

More about enVVeno Medical

Average Trading Volume: 954,336

Technical Sentiment Signal: Sell

Current Market Cap: $18.43M

Find detailed analytics on NVNO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1